Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US

SHANGHAI, March 19, 2023 /PRNewswire/ — Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus (SLE)…

Leave a Reply

Your email address will not be published. Required fields are marked *